We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Can Airflow Limitation in Chronic Obstructive Pulmonary Disease (COPD) be Reversible by Drugs?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01010178
Recruitment Status : Completed
First Posted : November 9, 2009
Last Update Posted : November 9, 2009
Information provided by:
Baqiyatallah Medical Sciences University

Brief Summary:
Critical combination of various approved drugs in management for patients suffering with COPD.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: Macrolid, Theophylline, Inhaler Corticosteroids Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Combination of Approved Drug in COPD
Study Start Date : February 2008
Primary Completion Date : April 2009
Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Macrolid, Theophylline, Corticosteroids
Approved drug in this setting
Drug: Macrolid, Theophylline, Inhaler Corticosteroids
we have no permission to include them in detail because of privacy policy of mentioned journal for publication

Primary Outcome Measures :
  1. 15% increasing in forced expiratory volume in 1 second [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   22 Years to 86 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • current or past smoker COPD

Exclusion Criteria:

  • history of significant occupational or other environmental exposures or a connective tissue disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01010178

Iran, Islamic Republic of
Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University, Mollasadra St,
Tehran, Iran, Islamic Republic of, 19945-546
Sponsors and Collaborators
Baqiyatallah Medical Sciences University

Responsible Party: Corresponding Author: Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University
ClinicalTrials.gov Identifier: NCT01010178     History of Changes
Other Study ID Numbers: BMT-1388-2
First Posted: November 9, 2009    Key Record Dates
Last Update Posted: November 9, 2009
Last Verified: November 2009

Keywords provided by Baqiyatallah Medical Sciences University:
symptoms PFT

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents